Evidence map›Paper›PMID 37770475›Full record

ArticleNPJ Parkinson's disease2023

Extracellular high molecular weight α-synuclein oligomers induce cell death by disrupting the plasma membrane.

Naohito Ito, Mayumi Tsuji, Naoki Adachi, Shiro Nakamura, Avijite Kumer Sarkar, Kensuke Ikenaka, César Aguirre, Atsushi Michael Kimura, Yuji Kiuchi, Hideki Mochizuki and 2 more

Open access · goldAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Naohito ItoDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan.
Mayumi TsujiPharmacological Research Center, Showa University, Tokyo, 142-8555, Japan. tsujim@med.showa-u.ac.jp.
Naoki AdachiDepartment of Physiology, School of Medicine, Showa University, Tokyo, 142-8555, Japan.
Shiro NakamuraDepartment of Oral Physiology, School of Dentistry, Showa University, Tokyo, 142-8555, Japan.
Avijite Kumer SarkarDepartment of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229-3026, USA.ORCID http://orcid.org/0000-0002-7646-6566
Kensuke IkenakaDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0002-5559-1966
César AguirreDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan.
Atsushi Michael KimuraBrain Research Institute Center for Integrated Human Brain Science, Department of Functional Neurology and Neurosurgery, Niigata University, Niigata, 951-8122, Japan.
Yuji KiuchiDepartment of Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan.
Hideki MochizukiDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan.
David B TeplowDepartment of Neurology, David Geffen School of Medicine, University of California-Los Angeles (UCLA), Los Angeles, LA, 10833, USA.ORCID http://orcid.org/0000-0002-2389-3417
Kenjiro OnoDepartment of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa University, Kanazawa, 920-8640, Japan. onoken@med.kanazawa-u.ac.jp.ORCID http://orcid.org/0000-0001-8454-6155
Showa University · JPThe University of Osaka · JPCincinnati Children's Hospital Medical Center · USKanazawa University · JPNiigata University · JPUniversity of California, Los Angeles · US

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) JP19K07965MEXT | Japan Society for the Promotion of Science (JSPS) JP22K07514
6 · The paper itself

Abstract

α-Synuclein (αS), the causative protein of Parkinson's disease and other α-synucleinopathies, aggregates from a low molecular weight form (LMW-αS) to a high molecular weight αS oligomer (HMW-αSo). Aggregated αS accumulates intracellularly, induces intrinsic apoptosis, is released extracellularly, and appears to propagate disease through prion-like spreading. Whether extracellular αS aggregates are cytotoxic, damage cell wall, or induce cell death is unclear. We investigated cytotoxicity and cell death caused by HMW-αSo or LMW-αS. Extracellular HMW-αSo was more cytotoxic than LMW-αS and was a crucial factor for inducing plasma membrane damage and cell death. HMW-αSo induced reactive oxygen species production and phospholipid peroxidation in the membrane, thereby impairing calcium homeostasis and disrupting plasma membrane integrity. HMW-αSo also induced extrinsic apoptosis and cell death by activating acidic sphingomyelinase. Thus, as extracellular HMW-αSo causes neuronal injury and death via cellular transmission and direct plasma membrane damage, we propose an additional disease progression pathway for α-synucleinopathies.

Identifiers

PMID37770475
PMCPMC10539356
OpenAlexW4387151661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.